Beating the Blues for Your Heart (BtB-Heart)
Computer-Based Depression Treatment to Reduce Coronary Artery Disease Risk
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University-Purdue University Indianapolis (IUPUI)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Primary care patients
- Age ≥40 years
- Clinically significant depressive symptoms (Patient Health Questionnaire-9 ≥10)
- No history of cardiovascular disease
Exclusion Criteria:
- Pregnant women
- A history of chronic disorders (HIV/AIDS, chronic kidney disease, systemic inflammatory disease, or past-year cancer)
- Current use of anticoagulants or vasodilators (antihypertensive and lipid-lowering medications are allowed)
- Current drinking problem
- History of bipolar disorder or psychosis
- Ongoing treatment for depression with a psychiatrist or psychologist/ counselor (antidepressants alone are allowed)
- Severe cognitive impairment
- Acute risk of suicide
- Significant vision or hearing problems
- Individuals who do not read or speak English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Beating the Blues (BtB)
An 8-session, empirically supported, computerized, cognitive-behavioral intervention for depression (www.beatingthebluesus.com)
|
BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics.
BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions.
General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention.
In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session.
A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
Other Names:
|
|
Other: Usual Care
Patients and their primary care providers were informed of the positive depression screen, and follow-up was encouraged.
|
Patients randomized to usual care will be informed that they have clinically significant depressive symptoms and will be encouraged to follow-up with their primary care physicians, who will receive a letter from our team indicating that their patient has elevated depressive symptoms and was randomized to the control condition.
The letter will also encourage physicians to follow-up with their patients and will provide a list of local mental health services.
Like those in the intervention group, usual care patients will continue to have access to and will receive any medical and mental health services that are part of usual care in the targeted health care systems.
Thus, there are no restrictions regarding the care that these patients can receive.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-Treatment Brachial Flow-Mediated Dilation (FMD) Adjusted for Pre-Treatment FMD
Time Frame: 12 weeks
|
Patients will undergo ultrasound assessment of brachial FMD in accordance with established guidelines.
After a 10-minute supine rest, high-resolution baseline images of the brachial artery will be obtained from 3 consecutive cardiac cycles.
Next, the forearm cuff will be inflated to 250 mmHg for 5 minutes and then will be rapidly deflated.
At 60 and 90 seconds post-deflation, images from 3 consecutive cardiac cycles will be acquired.
FMD values will be computed as the % change in brachial diameter at either 60 or 90 seconds after cuff deflation.
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-Treatment Depressive Symptoms Severity (SCL-20 Score) Adjusted for Pre-Treatment SCL-20 Score
Time Frame: 12 Weeks
|
Self-reported depressive symptom severity was measured at pre- (0 weeks) and post- (12 weeks) treatment visits by the 20 depression items from the Symptom Checklist 90 (Hopkins Symptom Checklist depression scale; SCL-20).
Each item on the scale ranges from 0 (not at all) to 4 (extremely).
Total scores are the average across all response items and range from 0 to 4 with higher scores indicating greater levels of depressive symptoms.
|
12 Weeks
|
|
Post-Treatment C-reactive Protein (CRP) Adjusted for Pre-Treatment CRP
Time Frame: 12 weeks
|
A marker of systemic inflammation measured from blood samples collected at pre- and post-treatment.
|
12 weeks
|
|
Post-Treatment Interleukin-6 (IL-6) Adjusted for Pre-Treatment IL-6
Time Frame: 12 weeks
|
A marker of systemic inflammation measured from blood samples collected at pre- and post-treatment.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jesse C. Stewart, Ph.D., Indiana University-Purdue Univerisity Indianapolis
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1105005448
- CRP4880000 (Other Grant/Funding Number: American Heart Association)
- 1703 (Other Identifier: Indiana Clinical Research Center)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.